Claudio Alejandro Pereira

Claudio Alejandro Pereira

Auto-generated profile, based on publicly available information

Claudio Alejandro Pereira

Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Médicas A. Lanari, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Instituto de Investigaciones Médicas (IDIM), Laboratorio de Parasitología Molecular, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
CPClaudio A. Pereira
Claudio A. Pereira
GAGuillermo Daniel Alonso
Guillermo Daniel Alonso
MPM.Cristina Paveto
M.Cristina Paveto
AIAdolfo Iribarren
Adolfo Iribarren
MCM.Laura Cabanas
M.Laura Cabanas
MFMirtha M. Flawiá
Mirtha M. Flawiá
This work contains the first description of a guanidino kinase in a flagellar unicellular parasite. The enzyme phosphorylates L-arginine and was characterized in preparations from Trypanosoma cruzi, the ethiological agent of Chagas' disease. The activity requires ATP and a divalent cation. Under standard assay conditions (1 mM L-arginine), the presence of 5-fold higher concentrations of canavanine or histidine produced a greater than 50% enzyme inhibition. The base sequence of this enzyme revealed an open reading frame of 357 amino acids and a molecular weight of 40,201. The amino acid sequence shows all of the characteristic consensus blocks of the ATP:guanidino phosphotransferase family and a putative "actinin-type" actin-binding domain. The highest amino acid identities of the T. cruzi sequence, about 70%, were with arginine kinases from Arthropoda. Southern and chromosome blots revealed that the kinase is encoded by a single-copy gene. Moreover, Northern blot analysis showed an mRNA subpopulation of about 2.0 kilobases, and Western blotting of T. cruzi-soluble polypeptides revealed a 40-kDa band. The finding in the parasite of a phosphagen and its biosynthetic pathway, which are totally different from those in mammalian host tissues, points out this arginine kinase as a possible chemotherapy target for Chagas' disease.

1 July 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CPCristina Paveto
Cristina Paveto
CPClaudio Pereira
Claudio Pereira
JEJoaquin Espinosa
Joaquin Espinosa
AMAndrea E. Montagna
Andrea E. Montagna
MFMarisa Farber
Marisa Farber
HTHéctor N. Torres
Héctor N. Torres
A nitric oxide synthase was partially purified from soluble extracts of Trypanosoma cruzi epimastigote forms. The conversion of L-arginine to citrulline by this enzyme activity required NADPH and was blocked by EGTA. The reaction was activated by Ca, calmodulin, tetrahydrobiopterin, and FAD, and inhibited by N-methyl-L-arginine. L-Glutamate and N-methyl-D-aspartate stimulated in vivo conversion of L-arginine to citrulline by epimastigote cells. These stimulations could be blocked by EGTA, MK-801, and ketamine and enhanced by glycine. A sodium nitroprusside-activated guanylyl cyclase activity was detected in cell-free, soluble preparations of T. cruzi epimastigotes. L-Glutamate, N-methyl-D-aspartate, and sodium nitroprusside increased epimastigote cyclic GMP levels. MK-801 bound specifically to T. cruzi epimastigote cells. This binding was competed by ketamine and enhanced by glycine or L-serine. Evidence thus indicates that in T. cruzi epimastigotes, L-glutamate controls cyclic GMP levels through a pathway mediated by nitric oxide.

17 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMelisa Saye
Melisa Saye
MMMariana Miranda
Mariana Miranda
FGFabio di Girolamo
Fabio di Girolamo
MCMaría de Los Milagros Cámara
María de Los Milagros Cámara
CPClaudio A. Pereira
Claudio A. Pereira
Trypanosoma cruzi, the etiological agent of Chagas' disease, has a metabolism largely based on the consumption of glucose and proline. This amino acid is essential for host cells infection and intracellular differentiation. In this work we identified a proline transporter (TcAAAP069) by yeasts complementation assays and overexpression in Trypanosoma cruzi epimastigotes. TcAAAP069 is mono-specific for proline but presents an unusual feature; the lack of stereospecificity, because it is competitively inhibited by the D- enantiomer. Parasites overexpressing TcAAAP069 have an increased intracellular proline concentration, 2.6-fold higher than controls, as a consequence of a higher proline transport rate. Furthermore, augmented proline concentration correlates with an improved resistance to trypanocidal drugs and also to reactive oxygen species including hydrogen peroxide and nitric oxide, emulating natural physiological situations. The IC50s for nifurtimox, benznidazole, H2O2 and NO. were 125%, 68%, 44% and 112% higher than controls, respectively. Finally, proline metabolism generates a higher concentration (48%) of ATP in TcAAAP069 parasites. Since proline participates on essential energy pathways, stress and drug resistance responses, these results provide a novel target for the development of new drugs for the treatments for Chagas' disease.

1 November 1999 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
CPClaudio A. Pereira
Claudio A. Pereira
GAGuillermo Daniel Alonso
Guillermo Daniel Alonso
MPM. Cristina Paveto
M. Cristina Paveto
MFMirtha M. Flawiá
Mirtha M. Flawiá
HTHéctor N. Torres
Héctor N. Torres

1 June 2006 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CCCarolina Carrillo
Carolina Carrillo
GCGaspar E. Canepa
Gaspar E. Canepa
IAIsrael D. Algranati
Israel D. Algranati
CPClaudio A. Pereira
Claudio A. Pereira

1 March 2005 in Current Drug Targets - Infectious Disorders
Verified
Journal Article
Closed access
PDF file
ASAriel Mariano Silber
Ariel Mariano Silber
WCWalter Colli
Walter Colli
Henning UlrichHenning Ulrich
Henning Ulrich
MAMaria Julia Manso Alves
Maria Julia Manso Alves
CPClaudio Alejandro Pereira
Claudio Alejandro Pereira
Abstract: Chagas disease is a zoonosis caused by the parasite Trypanosoma cruzi, a haematic protozoan, transmitted by insects from the Reduviidae family. This constitutes a relevant health and socio-economic problem in the Americas, with 11 - 18 million people infected, and approximately 100 million people at risk. The therapeutic possibilities rely into two drugs, nifurtimox® and benznidazole®, that were discovered more than thirty years ago, and are mainly successful during the acute phase of the disease. In the majority of the cases the disease is diagnosed in the chronic phase, when the therapy is inefficient and the probability of cure is low. In addition, these drugs are highly toxic, with systemic side effects on patients. Trypanosoma cruzi has a metabolism largely based on the consumption of amino acids, mainly proline, aspartate and glutamate, which constitute the main carbon and energy sources in the insect stage of the parasite life cycle. These amino acids also participate in the differentiation process of the replicative non-infective form (epimastigote) to the nonreplicative infective form (trypomastigote). In particular, the participation of proline in the intracellular differentiation cycle, which occurs in the mammalian host, was recently demonstrated. In addition, an arginine kinase has been described in T. cruzi and T. brucei, which converts free arginine to phosphoarginine, a phosphagen with a role as an energy reservoir. Arginine kinase seems to be an essential component of energy management during stress conditions. Taken together, these data indicate that amino acid metabolism may provide multiple as yet unexplored targets for therapeutic drugs.